Description
BPC-157 Oral-2 is an alternative packaging variant of oral BPC-157 - instead of 100 tablets, the compound comes in 60 capsules per pack. The substance itself is identical with the standard oral BPC-157 form; packaging variant differs in per-pack compound amount and capsule-instead-of-tablet form.
Per study reports pharmacology remains identical to standard BPC-157 Oral: pentadecapeptide with healing effects on tendons, ligaments, muscles, connective tissue, and gastrointestinal tract. Oral bioavailability is low compared to subcutaneous form, with advantage in local gastrointestinal research applications.
The capsule form has a practical advantage: better stomach tolerance for users finding tablets unpleasant. Some capsule formulations have enteric coating, which can theoretically improve bioavailability.
Pharmacokinetically orally bioavailable with moderate to low systemic bioavailability. Half-life after absorption several hours.
You can order BPC-157 Oral-2 as capsules in one bottle with 500mcg per capsule in 60-vials.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
BPC-157 Oral-2 is considered remarkably well tolerated per study reports. The substance is identical with standard oral BPC-157; the capsule form differs only in delivery.
Observed in research and user reports:
- Gastrointestinal tract: as an oral form, mild transient gastrointestinal observations are the most likely. The capsule form is perceived by some users as gentler on the stomach than tablets.
- Low systemic bioavailability: enzymatic degradation in the gastrointestinal tract substantially reduces systemic availability compared to the subcutaneous form - this is primarily an efficacy question, not a safety one.
- Circulation: isolated reports of brief fatigue or a feeling of warmth shortly after application.
- No long-term data: robust long-term human studies do not exist. The favorable safety profile rests primarily on animal models and short-term anecdotal experience.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs - Frontiers in Pharmacology 2022, He et al: PK profile across oral and parenteral routes.
- A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC - Journal of Physiology-Paris 1993, Sikiric et al: original characterization with gastric focus.
- Pentadecapeptide BPC 157 attenuates disturbances induced by neuroleptics: the effect on catalepsy and gastric ulcers in mice and rats - European Journal of Pharmacology 1999, Jelovac et al: intragastric administration in animal models.
- Stable gastric pentadecapeptide BPC 157 and wound healing - Frontiers in Pharmacology 2021, Seiwerth et al: mechanism review.
- Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat - Surgery Today 2008, Novinscak et al: muscle-healing study showing broader systemic action.
